Recursion Pharmaceuticals, Inc

Latest Results (07.10.2025):

Recursion Pharmaceuticals, Inc reported its second quarter of 2025 financial results, showcasing an increase in revenue driven by collaboration agreements while managing a rise in research and development and general administrative expenses. The company maintains a robust cash position, ensuring continued operational stability and strategic growth through the end of 2027.

Cash Position

As of June 30, 2025, Recursion Pharmaceuticals, Inc held $533.8 million in cash, cash equivalents, and restricted cash, down from $603.0 million as of December 31, 2024. The company anticipates that its current cash runway will extend into the fourth quarter of 2027 based on existing operating plans.

Revenue

Total revenue for the second quarter of 2025 was $19.2 million, an increase from $14.4 million in the second quarter of 2024. This growth was primarily driven by revenue from collaboration agreements.

Research and Development Expenses

Research and development expenses rose to $128.6 million for the second quarter of 2025, up from $73.9 million in the same quarter of the previous year. The increase was mainly due to the company's agreement with Tempus and the business combination with Exscientia in November 2024, which included $22.7 million in non-cash expenses related to the use of Tempus’ patient-centric multimodal oncology data under the ongoing collaboration.

General and Administrative Expenses

General and administrative expenses increased to $46.7 million for the second quarter of 2025, compared to $31.8 million in the second quarter of 2024. The rise was primarily due to the inclusion of G&A expenses from the business combination.